|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date03 Aug 2021 |
派安普利单抗注射液(10mL:100mg)在健康男性受试者中随机、单盲、平行设计的药代动力学和安全性的相似性临床研究
[Translation] A randomized, single-blind, parallel-designed pharmacokinetics and safety similarity clinical study of Pienpilimumab injection (10mL:100mg) in healthy male subjects
评价派安普利单抗注射液与安尼可在健康男性受试者单次静脉给药的药代动力学(PK)相似性。
评价派安普利单抗注射液与安尼可在健康男性受试者单次静脉给药的安全性。
[Translation] To evaluate the pharmacokinetic (PK) similarity of a single intravenous dose of Piamprimab Injection and Annicor in healthy male subjects.
To evaluate the safety of single-dose intravenous administration of Piamprimab Injection and Anicor in healthy male subjects.
100 Clinical Results associated with Zhengda Tianqing Kangfang (Shanghai) Biomedical Technology Co., Ltd.
0 Patents (Medical) associated with Zhengda Tianqing Kangfang (Shanghai) Biomedical Technology Co., Ltd.
100 Deals associated with Zhengda Tianqing Kangfang (Shanghai) Biomedical Technology Co., Ltd.
100 Translational Medicine associated with Zhengda Tianqing Kangfang (Shanghai) Biomedical Technology Co., Ltd.